TGFB1 and breast carcinoma: To this aim, highly metastatic MDA‐MB‐231 (henceforward MDA231) and poorly metastatic MCF7 breast cancer cells were treated with increasing concentrations of rhTGF‐β1 or CAF‐sEVs and the TGF‐β/SMAD signalling activity was evaluated.